Saturday 22 September 2018 ,
Saturday 22 September 2018 ,
Latest News
  • 44 killed as ferry capsizes in Tanzania
  • BNP slams govt for passing Digital Security Bill
  • Zia Charitable Trust graft trial to continue without Khaleda
  • Bangladesh second most gender equal country in Asia
  • Many AL leaders claim green signal from party chief
  • World ‘won’t rest’ on Rohingya crisis
  • World ‘won’t rest’ on Rohingya crisis
21 May, 2018 00:00 00 AM

FDA approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the treatment of anemia

FDA
FDA approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the treatment of anemia

The U.S. Food and Drug Administration recently approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.

“It is important for patients to have access to safe, effective and affordable biological products and we are committed to facilitating the development and approval of biosimilar and interchangeable products,” said Leah Christl, Ph.D., director of the Therapeutic Biologics and Biosimilars Staff in the FDA’s Center for Drug Evaluation and Research. “Biosimilars can provide greater access to treatment options for patients, increasing competition and potentially lowering costs.”

Biological products are generally derived from a living organism and can come from many sources, such as humans, animals, microorganisms or yeast. A biosimilar is a biological product that is approved based on data showing that it is highly similar to a biological product already approved by the FDA (reference product) and has no clinically meaningful differences in terms of safety, purity and potency (i.e., safety and effectiveness) from the reference product, in addition to meeting other criteria specified by law.

The FDA’s approval of Retacrit is based on a review of evidence that included extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates Retacrit is biosimilar to Epogen/Procrit. Retacrit has been approved as a biosimilar, not as an interchangeable product.

The most common side effects of epoetin alfa-treated patients in clinical studies of the reference product were high blood pressure, joint pain, muscle spasm, fever, dizziness, medical device malfunction, blood vessel blockage, respiratory infection, cough, rash, injection site irritation, nausea, vomiting, muscle pain, inflammation of the mouth and lips, weight decrease, reduction in white blood cells, bone pain, high blood sugar, insomnia, headache, depression, difficulty swallowing, low blood potassium, blood clots, itching, headache, injection site pain and chills.

Like Epogen/Procrit, Retacrit must be dispensed with a patient Medication Guide that provides information about the drug’s uses and risks. In addition, as with Epogen/Procrit, Retacrit contains a Boxed Warning to alert health care professionals and patients about increased risks of death, heart problems, stroke and tumor growth or recurrence. Additional warnings include high blood pressure, seizures, a condition in which the bone marrow stops making red blood cells thus causing anemia, serious allergic reactions and severe skin reactions.

The FDA granted approval of Retacrit to Hospira Inc., a Pfizer company.

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Communication between organs and organ  system is vital. It allows the body to adjust the function of each organ according to the needs of the whole…
What are hormones?

What are hormones?

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to…
Hormones 101 - what you really need to know

Hormones 101 - what you really need to know

While a great number of women in our culture develop some kind of sexual reproductive organ dysfunction, most are misled about true sexual and reproductive…
Hormonal imbalance

Hormonal imbalance

Hormones are your body’s chemical messengers. Produced in the endocrine glands, these powerful chemicals travel around your bloodstream telling…
New hormonal link suspected in type 2 diabetes

New hormonal link suspected in type 2 diabetes

Two disorders that often occur together -- type 2 diabetes and high blood pressure -- may have a common link in a hormone called aldosterone, researchers…
Deadly infections in kids: What you should know about sepsis

Deadly infections in kids: What you should know about sepsis

ITALO M. BROWN If you try on shoes barefoot, can you get a life-threatening infection? It turns out that this may have already happened, according to…
Signs of depression

Signs of depression

While only a qualified medical or mental health provider can diagnose depression, there are certain warning signs that can help you identify whether you…
Lack of exercise puts one in four people at risk, WHO says

Lack of exercise puts one in four people at risk, WHO says

Alex Therrien Very little progress has been made in reducing levels of inactivity worldwide, experts have warned. A WHO report estimates that more than…
Cancers 'rising around the world'

Cancers 'rising around the world'

Smitha Mundasad There will be 18.1 million new cases of cancer and 9.6 million people will die with the disease this year worldwide, a report predicts.…
Folic acid won't curb dangerous pregnancy complication

Folic acid won't curb dangerous pregnancy complication

High doses of folic acid do not protect pregnant women against a sometimes deadly complication called preeclampsia, a large trial suggests. The finding…
 FDA approves Jivi

FDA approves Jivi

Bayer receives FDA approval for Jivi (antihemophilic factor (recombinant), PEGylated-aucl) for prophylactic treatment of hemophilia A Bayer announced…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting